1. Home
  2. SLS vs LODE Comparison

SLS vs LODE Comparison

Compare SLS & LODE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLS
  • LODE
  • Stock Information
  • Founded
  • SLS 2012
  • LODE 2008
  • Country
  • SLS United States
  • LODE United States
  • Employees
  • SLS N/A
  • LODE N/A
  • Industry
  • SLS Biotechnology: Pharmaceutical Preparations
  • LODE Major Chemicals
  • Sector
  • SLS Health Care
  • LODE Industrials
  • Exchange
  • SLS Nasdaq
  • LODE Nasdaq
  • Market Cap
  • SLS 70.1M
  • LODE 79.6M
  • IPO Year
  • SLS N/A
  • LODE N/A
  • Fundamental
  • Price
  • SLS $1.06
  • LODE $0.30
  • Analyst Decision
  • SLS
  • LODE Buy
  • Analyst Count
  • SLS 0
  • LODE 1
  • Target Price
  • SLS N/A
  • LODE $2.60
  • AVG Volume (30 Days)
  • SLS 1.4M
  • LODE 16.7M
  • Earning Date
  • SLS 11-13-2024
  • LODE 02-26-2025
  • Dividend Yield
  • SLS N/A
  • LODE N/A
  • EPS Growth
  • SLS N/A
  • LODE N/A
  • EPS
  • SLS N/A
  • LODE N/A
  • Revenue
  • SLS N/A
  • LODE $1,864,811.00
  • Revenue This Year
  • SLS N/A
  • LODE $69.41
  • Revenue Next Year
  • SLS N/A
  • LODE $56.83
  • P/E Ratio
  • SLS N/A
  • LODE N/A
  • Revenue Growth
  • SLS N/A
  • LODE 117.46
  • 52 Week Low
  • SLS $0.50
  • LODE $0.13
  • 52 Week High
  • SLS $1.72
  • LODE $1.01
  • Technical
  • Relative Strength Index (RSI)
  • SLS 55.79
  • LODE 39.65
  • Support Level
  • SLS $0.87
  • LODE $0.26
  • Resistance Level
  • SLS $1.01
  • LODE $0.54
  • Average True Range (ATR)
  • SLS 0.08
  • LODE 0.12
  • MACD
  • SLS 0.01
  • LODE -0.04
  • Stochastic Oscillator
  • SLS 73.08
  • LODE 6.49

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

About LODE Comstock Inc.

Comstock Inc is engaged in technologies that efficiently use wasted and under-utilized natural resources to produce renewable energy and other products that contribute to balancing uses and emissions of carbon and enhance mineral and material discoveries. The segments of the company are Fuels Metals, Mining, Strategic Investments, and Corporate. The company derives maximum revenue from Strategic Investments segment. The Strategic Investments Segment includes minority equity investments in Quantum Generative Materials LLC (physics-based artificial intelligence), Green Li-ion Pte Limited (lithium-ion battery recycling and cathode production), Sierra Springs Opportunity Fund (strategic direct investment in northern Nevada real estate), and other equity or equity-linked investments.

Share on Social Networks: